RESUMEN
The role of paclitaxel-coated balloons has been established in the coronary and peripheral arterial circulations with recent interest in the use of paclitaxel-coated balloons to improve patency rates following angioplasty of arteriovenous fistulas. To assess the efficacy of paclitaxel-coated angioplasty balloons to prolong the survival time of target lesion primary patency in arteriovenous fistulas, we designed an investigator-led multi-center randomized controlled trial with follow up time variable for a minimum of one year. Patients with an arteriovenous fistula who were undergoing an angioplasty for a clinical indication were included but patients with one or more lesions outside the treatment segment were excluded. Following successful treatment with a high-pressure balloon, 212 patients were randomized. In the intervention arm, the second component was insertion of a paclitaxel-coated balloon. In the control arm, an identical procedure was followed, but using a standard balloon. The primary endpoint was time to loss of clinically driven target lesion primary patency. Primary analysis showed no significant evidence for a difference in time to end of target lesion primary patency between groups: hazard ratio 1.18 with a 95% confidence interval of 0.78 to 1.79. There were no significant differences for any secondary outcomes, including patency outcomes and adverse events. Thus, our study demonstrated no evidence that paclitaxel-coated balloons provide benefit, following standard care high-pressure balloon angioplasty, in the treatment of arteriovenous fistulas. Hence, in view of the benefit suggested by other trials, the role of paclitaxel-coated angioplasty balloons remains uncertain.
Asunto(s)
Angioplastia de Balón , Fístula Arteriovenosa , Derivación Arteriovenosa Quirúrgica , Fármacos Cardiovasculares , Angioplastia de Balón/efectos adversos , Derivación Arteriovenosa Quirúrgica/efectos adversos , Materiales Biocompatibles Revestidos , Humanos , Paclitaxel/efectos adversos , Diálisis Renal/efectos adversos , Factores de Tiempo , Resultado del Tratamiento , Grado de Desobstrucción VascularRESUMEN
BACKGROUND AND PURPOSE: Hematopoietic progenitor cells (HPCs) may attenuate the response to vascular injury by maintaining endothelial integrity and function. Our aim was to determine whether circulating HPC number and function correlate with restenosis after carotid endarterectomy. METHODS: HPC number (CD34(+)/CD133(+) cells), early colony-forming units, migratory capacity, and senescence were analyzed in blood collected preoperatively, 1 day, and 6 weeks postoperatively. Mobilizing cytokine levels were also measured. Stenosis was assessed by duplex scanning. RESULTS: HPC numbers (P<0.001) and early colony-forming unit count (P=0.001) fell rapidly 24 hours postoperatively. Restenosis at 6 months correlated negatively with the magnitude of postoperative falls in HPC numbers (R=-0.38, P=0.013) and early colony-forming unit counts (R=-0.42, P=0.008). The migratory capacity of preoperative HPCs correlated negatively with restenosis (R=-0.48, P=0.007). Preoperative SDF1 levels correlated with falls in HPC number (R=0.42, P=0.044) and early colony-forming unit counts (R=0.56, P=0.004). CONCLUSIONS: HPC function appears to be linked to the development of carotid artery restenosis after endarterectomy. These data support the concept that HPCs have a role in regulating remodeling of the injured arterial wall.
Asunto(s)
Estenosis Carotídea/sangre , Quimiocina CXCL12/sangre , Endarterectomía Carotidea , Endotelio Vascular/metabolismo , Células Madre Hematopoyéticas/metabolismo , Regeneración , Antígeno AC133 , Anciano , Anciano de 80 o más Años , Antígenos CD/sangre , Antígenos CD34/sangre , Estenosis Carotídea/patología , Estenosis Carotídea/cirugía , Endotelio Vascular/lesiones , Endotelio Vascular/patología , Femenino , Glicoproteínas/sangre , Células Madre Hematopoyéticas/patología , Humanos , Masculino , Persona de Mediana Edad , Péptidos/sangreRESUMEN
OBJECTIVE: Angiogenic factors are expressed within thrombus during resolution, but the primary stimulus for neovascularization is unknown. Our aims were to determine whether (1) hypoxia and hypoxia-inducible factor 1α (HIF1α) are induced in resolving thrombus, (2) this stimulates angiogenic factor production, and (3) upregulating HIF1α enhances thrombus resolution and vein recanalization. METHODS AND RESULTS: Oxygen tension in the thrombus was negatively correlated with HIF1α levels (Spearman correlation [RS] = -0.77, P<0.0001), whereas HIF1α levels positively correlated with vascular endothelial growth factor (VEGF) expression (Pearson correlation [R] = 0.85, P<0.0005), during resolution in a murine model. HIF1α (P<0.005), VEGF (P<0.005), and VEGF receptor 1 (VEGFR1) (P<0.05) expression was 2-fold greater in the thrombus of mice treated with the prolyl hydroxylase domain inhibitor L-mimosine compared with controls. The levels of 13 other HIF1-mediated angiogenic factors were also increased. Thrombus weight (P<0.001) and volume (P<0.05) were reduced by a third in l-mimosine-treated mice compared with controls, whereas vein recanalization (P<0.005) and thrombus neovascularization (P<0.001) were 2-fold greater, and this was associated with increased inflammatory cell content. CONCLUSIONS: Hypoxia and HIF1α are induced in the naturally resolving thrombus and correlate with increased angiogenic factor expression. Upregulation of HIF1α enhances thrombus resolution and vein recanalization. HIF1α may represent a novel target for treatments that promote resolution and recanalization and reduce the incidence of post-thrombotic syndrome.
Asunto(s)
Hipoxia de la Célula , Subunidad alfa del Factor 1 Inducible por Hipoxia/metabolismo , Neovascularización Fisiológica , Oxígeno/metabolismo , Vena Cava Inferior/metabolismo , Trombosis de la Vena/metabolismo , Animales , Citocinas/metabolismo , Modelos Animales de Enfermedad , Inhibidores Enzimáticos/farmacología , Macrófagos/inmunología , Masculino , Ratones , Ratones Endogámicos BALB C , Mimosina/farmacología , Neovascularización Fisiológica/efectos de los fármacos , Infiltración Neutrófila , Neutrófilos/inmunología , Procolágeno-Prolina Dioxigenasa/antagonistas & inhibidores , Procolágeno-Prolina Dioxigenasa/metabolismo , Factores de Tiempo , Regulación hacia Arriba , Factor A de Crecimiento Endotelial Vascular/metabolismo , Receptor 1 de Factores de Crecimiento Endotelial Vascular/metabolismo , Vena Cava Inferior/efectos de los fármacos , Vena Cava Inferior/inmunología , Trombosis de la Vena/inmunología , Trombosis de la Vena/fisiopatologíaRESUMEN
OBJECTIVES: We investigated the safety of donor nephrectomy from older adult donors (age ≥60 years), as well as long-term donor, recipient, and graft outcomes. MATERIALS AND METHODS: We retrospectively analyzed data from 307 living donor kidney transplants from 1996 to 2016 and defined 2 cohorts based on donor age. Cohort A comprised donors aged 60 years and older, and cohort B comprised donors from 18 to 59 years old. We recorded donor and recipient perioperative complications, outcomes, and survival rates and used SPSS and MedCalc statistical software programs for data analyses. RESULTS: The mean follow-up period for donor-recipient pairs in cohort A was 97 months (SD, 25.1 months) with median 108 months (IQR, 92-108 months) and in cohort B was 100.57 months (SD, 25.45 months) with median 120 months (IQR, 84-120 months). Mean donor age in cohort A was 64.13 years (SD, 3.78 years) with median 63 years (IQR, 61-66.5 years) and in cohort B was 41.08 years (SD, 9.15 years) with median 41 years (IQR, 34.5-48 years) (P < .001, cohort A vs B). Mean recipient age in cohort A was 47.65 years (SD, 14.26 years) with median 48.5 years (IQR, 35.5-61 years) and in cohort B was 43.55 years (SD, 13.15 years) with median 40.5 years (IQR, 33.5-54 years) (P < .001, cohort A vs B). Both cohorts showed no significant differences in perioperative donor and recipient complications. Renal function (measured as estimated glomerular filtration rate) in remaining native kidneys of cohort A showed no significant decline during median 8-year follow-up (P = .089 and P < .414, respectively). There were no significant differences in survival rates for donors, recipients, and grafts. CONCLUSIONS: Living donor kidney transplant from older adult donors is safe and effective with good long-term patient and allograft survival.
Asunto(s)
Trasplante de Riñón , Donadores Vivos , Adolescente , Adulto , Anciano , Supervivencia de Injerto , Humanos , Trasplante de Riñón/efectos adversos , Persona de Mediana Edad , Estudios Retrospectivos , Donantes de Tejidos , Resultado del Tratamiento , Adulto JovenRESUMEN
Current guidelines advocate the use of capsule endoscopy (CE) when gastroscopy and colonoscopy have failed to demonstrate the origin of occult gastrointestinal bleeding. CE has been used successfully in the diagnosis of a variety of conditions such as coeliac disease, polyposis syndromes and small bowel tumours, when routine investigations have failed to yield a diagnosis. In conditions where the diameter of the bowel lumen may be compromised, such as Crohn's disease, CE is contraindicated because of the risk of retention and/or small bowel obstruction. Here we present an unusual case where CE resulted in small bowel obstruction and perforation in a segment of small bowel which had become inflamed secondary to a carcinoid tumour.
Asunto(s)
Endoscopía Capsular/efectos adversos , Tumor Carcinoide/complicaciones , Enfermedades del Íleon/etiología , Neoplasias Intestinales/complicaciones , Obstrucción Intestinal/etiología , Perforación Intestinal/etiología , Síndrome Carcinoide Maligno/complicaciones , Anciano , Tumor Carcinoide/diagnóstico , Humanos , Neoplasias Intestinales/diagnóstico , Masculino , Síndrome Carcinoide Maligno/diagnósticoRESUMEN
INTRODUCTION: Venous thrombus resolution may be regulated by an angiogenic process that involves the surrounding vein wall. The aims of this study were to determine whether: (i) thrombosis stimulates activation of the angiogenic transcription factor, hypoxia-inducible factor (HIF) 1α, and downstream expression of growth factors in vein wall; and (ii) upregulation of HIF1α in vein wall leads to increased growth factor expression and enhanced thrombus resolution. MATERIALS AND METHODS: HIF1α, vascular endothelial growth factor (VEGF), and placental growth factor (PLGF) were quantified in mouse inferior vena cava (IVC) at days 1, 3, 7, and 14 after thrombus formation (n = 10-13 per group). An additional group of thrombosed mice were treated with the prolyl-hydroxylase domain (PHD) inhibitor, L-mimosine (L-mim) or vehicle control. HIF1α, VEGF, and PLGF in IVC were measured at days 1 and 7; and vein recanalisation and thrombus resolution were measured at days 7 and 10 (n = 6-7 per group). RESULTS: HIF1α was expressed in thrombosed IVC and its levels remained relatively constant throughout natural resolution. The levels of VEGF in thrombosed IVC were elevated at days 1 (P < 0.0001) and 3 (P < 0.05); and PLGF at days 1 (P < 0.0001), 3 (P < 0.0001), and 7 (P < 0.0001). Treatment with L-mim led to: increased HIF1α (P<0.05), VEGF (P < 0.005), and PLGF (P < 0.001) levels in the IVC; decreased thrombus size (P < 0.01); and increased vein recanalisation (P < 0.001). CONCLUSIONS: HIF1α levels in vein wall are not affected by thrombosis and it appears that the angiogenic drive in the vein surrounding resolving thrombus is regulated independently of HIF1α. Stimulating HIF1α levels in the vein wall leads to an increased angiogenic drive and promotes vein recanalisation and thrombus resolution.
Asunto(s)
Subunidad alfa del Factor 1 Inducible por Hipoxia/metabolismo , Vena Cava Inferior/metabolismo , Trombosis de la Vena/metabolismo , Animales , Modelos Animales de Enfermedad , Inhibidores Enzimáticos/farmacología , Masculino , Ratones , Ratones Endogámicos BALB C , Mimosina/farmacología , Neovascularización Fisiológica , Factor de Crecimiento Placentario , Proteínas Gestacionales/metabolismo , Procolágeno-Prolina Dioxigenasa/antagonistas & inhibidores , Procolágeno-Prolina Dioxigenasa/metabolismo , Factores de Tiempo , Regulación hacia Arriba , Factor A de Crecimiento Endotelial Vascular/metabolismo , Vena Cava Inferior/efectos de los fármacos , Vena Cava Inferior/patología , Trombosis de la Vena/tratamiento farmacológico , Trombosis de la Vena/patología , Trombosis de la Vena/fisiopatologíaAsunto(s)
Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/metabolismo , Vena Cava Inferior/metabolismo , Trombosis de la Vena/metabolismo , Animales , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/agonistas , Modelos Animales de Enfermedad , Fibrinolíticos/farmacología , Masculino , Ratones Endogámicos BALB C , Mimosina/farmacología , Transducción de Señal/efectos de los fármacos , Factores de Tiempo , Regulación hacia Arriba , Vena Cava Inferior/efectos de los fármacos , Vena Cava Inferior/patología , Trombosis de la Vena/tratamiento farmacológico , Trombosis de la Vena/patologíaAsunto(s)
Cálculos Biliares/complicaciones , Enfermedades del Íleon/etiología , Ileus/etiología , Anciano de 80 o más Años , Colecistectomía , Diagnóstico Diferencial , Femenino , Cálculos Biliares/diagnóstico , Cálculos Biliares/cirugía , Humanos , Enfermedades del Íleon/diagnóstico , Enfermedades del Íleon/cirugía , Ileus/diagnóstico , Ileus/cirugía , Tomografía Computarizada por Rayos XAsunto(s)
Adenoviridae/genética , Subunidad alfa del Factor 1 Inducible por Hipoxia/biosíntesis , Subunidad alfa del Factor 1 Inducible por Hipoxia/genética , Trombosis de la Vena/terapia , Animales , Vectores Genéticos/genética , Proteínas Fluorescentes Verdes/biosíntesis , Proteínas Fluorescentes Verdes/genética , Ratones , Trombosis de la Vena/genética , Trombosis de la Vena/metabolismoAsunto(s)
Fibronectinas/química , Fibronectinas/metabolismo , Factor A de Crecimiento Endotelial Vascular/metabolismo , Trombosis de la Vena/metabolismo , Animales , Sitios de Unión , Fibronectinas/genética , Regulación de la Expresión Génica , Masculino , Metaloproteinasa 9 de la Matriz/metabolismo , Ratones , Ratones Endogámicos BALB C , Unión Proteica , Estructura Terciaria de Proteína , Venas/metabolismo , Trombosis de la Vena/genéticaRESUMEN
Peer-assisted learning (PAL) is a useful learning method. PAL is learning through active help of peer group members. PAL is increasingly being used in medical education although documented experience to date is limited. A PAL programme has been instigated and run by students at a Scottish medical school. The experience has resulted in the formulation of 12 tips to running PAL. These 12 tips cover organizational issues, tutor selection, training the tutor, and running and evaluating the sessions. It is hoped that these tips will be useful in the initiation and running of PAL programmes in other institutions.